Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins

BACKGROUND: There exists a subpopulation of T2DM in whom first-line doses of statin are insufficient for optimally reducing LDL-C, representing a major risk of CVD. The RESEARCH study focuses on LDL-C reduction in this population along with modifications of the lipid profiles leading to residual ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Kentaro, Kawamura, Mitsunobu, Kohro, Takahide, Omura, Masao, Watanabe, Takayuki, Ashidate, Keiko, Horiuchi, Toshiyuki, Hara, Hidehiko, Sekine, Nobuo, Chin, Rina, Tsujino, Motoyoshi, Hiyoshi, Toru, Tagami, Motoki, Tanaka, Akira, Mori, Yasumichi, Inazawa, Takeshi, Hirano, Tsutomu, Yamazaki, Tsutomu, Shiba, Teruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580589/
https://www.ncbi.nlm.nih.gov/pubmed/26398887
http://dx.doi.org/10.1371/journal.pone.0138332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580589/
https://www.ncbi.nlm.nih.gov/pubmed/26398887
http://dx.doi.org/10.1371/journal.pone.0138332

Ejemplares similares